Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis

Scandinavian Journal of Rheumatology

Volumn 39, Issue 2, 2010, Pages 155-159

  Colaci, M ^a   Sebastiani, M ^a   Giuggioli, D ^a   Manfredi, A ^a   Spagnolo, P ^a   Luppi, F ^a   Richeldi, L ^a   Ferri, C ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG ALVEOLITIS; LUNG LAVAGE; MALE; PRIORITY JOURNAL; SCLERODERMA; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; BRONCHOALVEOLAR LAVAGE; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 77950198788     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740903270581     Document Type: Article

References (17)

1. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002;81:139-153
2. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10.
3. Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol 2007;19:611-618
4. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, et al. Bronchoalveolar lavage and response to cyclophosphamiDe in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008;177:91-98
5. Mittoo S,Wigley FM,Wise R, Xiao H, Hummers L. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamiDe treatment in scleroderma patients with interstitial lung disease. Arthritis Rheum 2007;56:4195-4202
6. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. CyclophosphamiDe versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-2666
7. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. CyclophosphamiDe is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-954
8. Várai G, Earle L, Jimenez SA, Steiner RM, Varga J. A pilot study of intermittent intravenous cyclophosphamiDe for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998;25: 1325-1329
9. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, et al. CyclophosphamiDe pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29:731-736
10. Kowal-Bielecka O, Kowal K, Rojewska J, Bodzenta-Lukaszyk A, Siergiejko Z, Sierakowska M, et al. CyclophosphamiDe reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 2005;64:1343-1346
11. Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, Konig G, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996;154:400-406
12. Witt C, Borges AC, John M, Fietze I, Baumann G, Krause A. Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999;58:635-640
13. Goh NS, VeeraraghaVan S, Desai SR, Cramer D, Hansell DM, Denton CP, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007;56:2005-2012
14. Clements PJ, Goldin JG, Kleerup EC, Furst DE, Elashoff RM, Tashkin DP, et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004;50: 1909-1917
15. Baughman RP, Raghu G. Bronchoalveolar cellular analysis in scleroderma lung disease: does Sutton's law hold? Am J Respir Crit Care Med 2008;177:2-3.
16. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamiDe on outcomes at 2 years in scleroderma lung disease. Am J Resp Crit Care Med 2007;76:1026-1034
17. Kowal-Bielecka O, Kowal K, Highland KB, Silver RM. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. Semin Arthritis Rheum 2009; (Epub ahead of print doi:10.1016/j.semarthrit.2008.10.009).